

30 November 2011

## TENDER RESULTS

The PHARMAC Board (or Acting Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2009/10 Invitation to Tender, dated 4 December 2009.

As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – [www.pharmac.govt.nz/schedule.asp](http://www.pharmac.govt.nz/schedule.asp).

Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

**2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

<b>Chemical Name</b>	<b>Presentation; Pack size and type</b>	<b>Current subsidy and price</b>	<b>New subsidy and price</b>	<b>Sole supply brand (Supplier)</b>	<b>Date of listing/subsidy change for tender winning brand</b>	<b>Date of reference pricing of other listed brands</b>	<b>Sole Subsidised Supply date (and delisting of other listed brands)</b>	<b>Brand (Supplier) affected by reference pricing and delisting</b>
Brimonidine tartrate	Eye drops 0.2%; 5 ml OP, 1 dropper	\$7.93	\$6.45	Arrow-Brimonidine (Arrow)	1 May 2012	1 July 2012	1 October 2012	AFT (AFT)
Octreotide (somatostatin analogue)	Inj 50 mcg per ml, 1 ml; 5 ampoules	\$25.65 (Hospira) \$43.50 (Novartis)	\$19.24	Octreotide MaxRx (Max Health)	1 June 2012	1 August 2012	1 November 2012	Hospira (Hospira) Sandostatin (Novartis)
Octreotide (somatostatin analogue)	Inj 100 mcg per ml, 1 ml; 5 ampoules	\$48.50 (Hospira) \$81.00 (Novartis)	\$36.38	Octreotide MaxRx (Max Health)	1 June 2012	1 August 2012	1 November 2012	Hospira (Hospira) Sandostatin (Novartis)
Octreotide (somatostatin analogue)	Inj 500 mcg per ml, 1 ml; 5 ampoules	\$175.00 (Hospira) \$399.00 (Novartis)	\$131.25	Octreotide MaxRx (Max Health)	1 June 2012	1 August 2012	1 November 2012	Hospira (Hospira) Sandostatin (Novartis)

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Imipenem with cilastatin	Inj 500 mg with cilastatin 500 mg; 1 vial	\$21.61	\$18.37	Primaxin (MSD)	1%	1 January 2012	1 March 2012

3. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Brimonidine tartrate	Eye drops 0.2%; 5 ml OP, 1 dropper	\$7.93	\$6.45	Arrow-Brimonidine (Arrow)	1%	1 May 2012	1 July 2012	AFT (AFT)
Meropenem	Inj 500 mg; 1 glass vial	\$25.50	\$10.50	Penembact (InterPharma)	1%	1 January 2012	1 March 2012	Merrem (AstraZeneca)
Meropenem	Inj 1 g; 1 glass vial	\$50.50	\$21.00	Penembact (InterPharma)	1%	1 January 2012	1 March 2012	Merrem (AstraZeneca)
Octreotide (somatostatin analogue)	Inj 50 mcg per ml, 1 ml; 5 ampoules	\$25.65	\$19.24	Octreotide MaxRx (Max Health)	1%	1 June 2012	1 August 2012	Hospira (Hospira)
Octreotide (somatostatin analogue)	Inj 100 mcg per ml, 1 ml; 5 ampoules	\$48.50	\$36.38	Octreotide MaxRx (Max Health)	1%	1 June 2012	1 August 2012	Hospira (Hospira)
Octreotide (somatostatin analogue)	Inj 500 mcg per ml, 1 ml; 5 ampoules	\$175.00	\$131.25	Octreotide MaxRx (Max Health)	1%	1 June 2012	1 August 2012	Hospira (Hospira)

**2009/10 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2013**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

4. Tenders awarded to pharmaceuticals where no brand is listed.

<b>Chemical name</b>	<b>Presentation; Pack size and type</b>	<b>Subsidy and price</b>	<b>Sole supply brand (Supplier)</b>	<b>Date of listing</b>	<b>Sole Subsidised Supply date</b>
*Bisoprolol Fumarate	Tab 2.5 mg; 30 tablets	\$3.88	Bosvate (Douglas)	1 April 2012	1 July 2012
*Bisoprolol Fumarate	Tab 5 mg; 30 tablets	\$4.74	Bosvate (Douglas)	1 April 2012	1 July 2012
*Bisoprolol Fumarate	Tab 10 mg; 30 tablets	\$9.18	Bosvate (Douglas)	1 April 2012	1 July 2012

\*Bisoprolol Fumarate will also be listed in Section H of the Pharmaceutical Schedule but will not have Hospital Supply Status.

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Acting Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.